Annovis Bio

Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease

BERWYN, PA — In a recent breakthrough, Annovis Bio (NYSE: ANVS), a biopharmaceutical company, has successfully performed measurements of critical biomarkers in the plasma of Parkinson’s disease patients. Utilizing buntanetap, …

Annovis Bio’s Buntanetap Demonstrates Potential to Lower Key Biomarkers in Parkinson’s Disease Read More

Annovis Bio

Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced recent approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (“PD”).

Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap Read More